Ann F. Hanham

Managing Director

Prior to joining Burrill & Company, Ann Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune Pharmaceuticals, and prior to that, the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and the Medical Director for Celtrix Pharmaceuticals. She has also worked for Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program, and as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada.

Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986. She currently is a member of the Board of Directors of Adlyfe, Elbion, Endocyte, Logical Therapeutics, and Neosil.